Cormedix Earnings Call Highlights Growth, Raises Outlook

Cormedix Inc. ((CRMD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cormedix Inc.’s latest earnings call projected a generally upbeat tone, underscored by sharp revenue and EBITDA outperformance and a sizable guidance raise. Management highlighted strong uptake of DefenCath, solid contributions from the Melinta acquisition, and encouraging Phase III data for REZZAYO, while acknowledging reimbursement and clinical trial timing risks that could temper results beyond 2026.

Explosive Revenue Growth and Margin Expansion

Cormedix reported Q1 2026 net revenue of $127.4 million, more than tripling the $39.1 million posted a year earlier as DefenCath and Melinta products drove the surge. Adjusted EBITDA jumped to $70 million from $23.6 million, signaling robust margin expansion and a more profitable core business as scale benefits and mix improvements flowed through.

Upgraded Full-Year Outlook

On the back of its strong start, the company lifted full-year 2026 net revenue guidance to a range of $325 million to $345 million, up from $300 million to $320 million. Adjusted EBITDA is now projected between $115 million and $135 million, versus prior expectations of $100 million to $125 million, reflecting increased confidence in DefenCath demand and portfolio performance.

DefenCath Utilization and Clinical Validation

DefenCath delivered Q1 sales of $97.5 million, with management emphasizing durable utilization gains and higher customer run rates as use expanded from the fourth quarter into the first. Large dialysis providers such as U.S. Renal Care, IRC and Fresenius reported or announced favorable real-world outcomes, which management believes are reinforcing clinical confidence and supporting broader adoption.

REZZAYO Phase III Success Sets Up Next Growth Driver

The Phase III ReSPECT trial for REZZAYO met its primary endpoint, showing non-inferior fungal-free survival at day 90 versus standard therapy and covering Candida, Aspergillus and nosocomial infections. The program also delivered favorable safety data with fewer treatment-emergent adverse events leading to dose changes or withdrawal, and the company is preparing a supplemental filing targeted for the second half of 2026 with a potential launch in 2027.

Cash Generation Strengthens Balance Sheet Flexibility

Cormedix exited Q1 with $178.1 million in cash after generating $42.4 million in operating cash flow despite sizable incentive rebate payments. Cash increased by $33.3 million during the quarter, and the company deployed $11.1 million toward share repurchases, giving management financial flexibility for pipeline investment, commercial expansion and potential future capital returns.

Melinta Acquisition Boosts Scale and Diversification

The August 2025 Melinta acquisition contributed $29.9 million of revenue in Q1 2026, underlining its role in accelerating top-line growth and diversifying the portfolio. Management highlighted that Melinta’s assets and related pediatric and biodefense development programs are broadening Cormedix’s strategic footprint beyond DefenCath and adding new levers for long-term growth.

TDAPA Sunset Creates Reimbursement Overhang

Investors were reminded that the initial transitional add-on payment adjustment for new and innovative dialysis drugs expires on June 30, 2026, introducing revenue volatility for DefenCath in the back half of 2026. As CMS shifts to a post-TDAPA add-on methodology, management is planning for price erosion in the third and fourth quarters while focusing on preserving and expanding patient utilization to support longer-term value.

Near-Term Inventory Dynamics and One-Time Q1 Benefit

Management cautioned that second-quarter results will effectively reflect a two-month revenue period because the largest customer is expected to reduce inventories by roughly four weeks. As a result, Q2 DefenCath sales are projected around $60 million, plus or minus a few million, and investors were reminded that Q1 benefited from a one-time $9 million favorable adjustment to a prior sales estimate.

Delayed TPN Trial Extends Timeline to 2028

The NUTRI-GAURD TPN Phase III program has enrolled only about a third of the 90 patients needed for an interim analysis, as lower-than-expected infection rates and operational challenges slowed recruitment. Cormedix plans to amend the protocol, add more sites including five in Turkey, and potentially revise the statistical plan, but now expects overall study completion to slip into 2028, pushing out a potential new revenue stream.

Non-Operating Volatility Weighs on GAAP Results

Quarterly GAAP earnings were pressured by about $25 million of non-operating expenses tied to mark-to-market adjustments on marketable equity securities and contingent consideration. Management noted a GAAP tax rate near 28 percent, explaining that while net operating losses may lower cash taxes, reported tax expense will continue to align with statutory levels, adding noise to bottom-line metrics.

Rising Operating Costs Reflect Scale-Up

Operating expenses climbed to $41.5 million in the quarter, including $7.2 million for R&D, $12.5 million for sales and marketing, and $21.7 million for G&A, reflecting the larger combined entity and investments in people, commercial capabilities and IT. Branded prescription fees associated with Melinta’s products also contributed, and management guided full-year cash operating expenses to between $145 million and $160 million as the company continues to build out its infrastructure.

Medicare Mix and Potential Upside From Payer Deals

Management highlighted that more than 90 percent of DefenCath patients are covered under traditional Medicare fee-for-service, which currently anchors the revenue base. They pointed to Medicare Advantage contracting as a meaningful potential upside lever, but noted that limited near-term penetration leaves results highly dependent on future payer negotiations and the timing of any new agreements.

Guidance and Outlook Emphasize Growth With Guardrails

Looking ahead, Cormedix now expects full-year 2026 net revenue of $325 million to $345 million and adjusted EBITDA of $115 million to $135 million, underpinned by DefenCath sales of $175 million to $195 million and cash operating expenses of $145 million to $160 million. The outlook incorporates planned hiring of 15 to 20 commercial and medical staff in the second half, flags potential DefenCath volatility around the mid-2026 reimbursement reset, and does not factor in upside from new customers or additional Medicare Advantage wins.

Cormedix’s earnings call painted a picture of a company in high-growth mode, with DefenCath momentum, REZZAYO progress and Melinta integration driving upgraded expectations. While reimbursement changes, non-operating swings and delayed TPN timelines present real risks, management’s raised guidance, strong cash generation and expanding pipeline left investors with a broadly constructive narrative for the coming years.